Search Results 341-350 of 24169 for prostate cancer

  1. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) - Mayo Clinic

    A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate ...

  2. Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study - Mayo Clinic

    Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study. Print details.

  3. Mayo Clinic Minute: Improvements in prostate surgery Video Audio

    "Surgery is a common treatment for prostate cancer, especially when we can confirm that the tumor is contained to the prostate. Obviously, physically.

  4. A Study to Identify Genetic Markers in Non-Cancerous Prostate Tissues, and Compare to Better Identify the Markers Unique to Prostate Cancer - Mayo Clinic

    ... prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.

  5. Living With Cancer: Recognizing lung cancer - Mayo Clinic News Network

    Lung cancer is the leading cause of cancer deaths in the U.S. Lung cancer claims more lives each year than colon, prostate, ovarian and breast cancers combined.

  6. Publications - John Thomas, M.B.B.S., M.D. - Mayo Clinic

    ... prostate cancer found on systematic biopsy. Prostate Cancer Prostatic Dis. 2018 Nov; 21 (4):549-555 Epub 2018 July 09. View PubMed; McNamara MM, Thomas JV ...

  7. Men’s Cancer Conference 2007

    Topics include bone health, nutrition, PSA monitoring, erectile dysfunction and incontinence. What to Expect from Prostate Cancer Treatment. Bradley Leibovich, ...

  8. FDA approves earlier use of lutetium Lu 177 vipivotide tetraxetan for patients with PSMA-positive metastatic castration-resistant prostate cancer - Mayo Clinic

    ... prostate cancer. Aug. 20, 2025. Since 2022, lutetium Lu 177 vipivotide tetraxetan has been used to treat prostate-specific membrane antigen (PSMA)-positive ...

  9. 64Cu-SAR-bisPSMA And 67Cu-SAR-bisPSMA For Identification And Treatment Of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) - Mayo Clinic

    The purpose of this study is to evaluate 64Cu-SAR-bisPSMA and 67Cu-ARbisPSMA administered to participants with metastatic castrate resistant prostate cancer ( ...

  10. Mayo Clinic Urologists Present Findings at American Urological Association Annual Meeting

    For the study, "Adjuvant Hormonal Therapy Does Not Adversely Impact Overall Survival Following Radical Prostatectomy for Men with High Risk Prostate Cancer When ...